DashboardAll companies
Run this on your own research
Healthcare · Diagnostics & Research

Natera Inc.

NTRANASDAQ$403.95+$2.58 (+0.64%)Market closed

Price Chart

Daily

Key facts

Market Cap
$57.88B
P/E
−265.3x
P/B
32.25x
ROE
−14.3%

Natera Inc.

Healthcare · Diagnostics & Research · FY 2025

Natera Inc., a leading player in the life sciences and diagnostics industry, specializes in developing cell-free DNA testing technologies. This biotechnological firm primarily focuses on non-invasive genetic testing, assisting in maternal-fetal medicine through the screening of high-risk pregnancies with its flagship product, Panorama. In addition to prenatal screening, Natera offers genetic solutions for oncology and organ health, providing critical insights through its comprehensive suite of products. These offerings are especially significant in cancer diagnostics, where Natera's technology helps in early detection, monitoring, and guiding treatment options. The company's innovative approach to DNA analysis enables the identification of genetic conditions and the monitoring of health trends with precision and ease, impacting healthcare providers, patients, and researchers. With its headquarters in San Carlos, California, Natera Inc. is at the forefront of genetic testing advancements, playing a pivotal role in personalizing medicine and revolutionizing patient care by enhancing early diagnosis capabilities and improving clinical outcomes.

CEO
Mr. Steven Leonard Chapman
Employees
3,282
Website
natera.com

Company Statistics

Valuation

P/E
−265.3x
P/B
32.25x
P/S
23.95x
EV/EBITDA
−246.5x
P/FCF
725.6x

Margins

Gross
64.7%
EBITDA
−9.6%
Operating
−13.4%
Pre-Tax
−11.6%
Net
−9.0%

Returns

ROA
−10.3%
ROE
−14.3%
ROIC
−13.0%

Growth (CAGR)

Rev 3Yr
41.1%
Rev 5Yr
42.6%
Op Inc 3Yr
—
Net Inc 3Yr
—

Financial Health

Cash & Cash Equivalents
$1.08B
Net Debt
−$390.2M
Debt/Equity
40.1%
Interest Cov
—

Profile

Revenue
$2.31B
Shares Out
—
Public markets · Korea, US, Japanalpha-lenz.com · Core by Treasurer
Natera Inc. (NTRA) Stock Forecast 2026 $403.95 — Price, Financials & Analyst Targets | AlphaLenz